ArticleGenomics & informatics2026
Design and in silico evaluation of PV-GNProtecta: an mRNA multi-epitope vaccine candidate against Puumala virus using immunoinformatics and structural analysis.
Article in Genomics & informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Puumala virus (PUUV), the principal causative agent of nephropathia epidemica (NE), poses a significant public health threat due to its zoonotic transmission, renal complications, and the lack of an approved vaccine. In this study, an immunoinformatics-driven mRNA multi-epitope vaccine, PV-GNProtecta, was designed using conserved regions of the viral glycoprotein (G) and nucleoprotein (N). Highly antigenic, non-allergenic, and non-toxic T-cell and B-cell epitopes were identified and assembled with appropriate adjuvants to enhance immunogenicity. Population coverage analysis suggested broad HLA responsiveness across diverse populations. The vaccine construct exhibited favorable physicochemical properties, including stability, solubility, and antigenicity. Structural validation predicted high model quality, with 95.5% of residues located in favored Ramachandran regions and an ERRAT score of 91.4. Molecular docking and MM-GBSA analyses predicted favorable computational interactions between PV-GNProtecta and TLR4, while a 100 ns molecular dynamics simulation provided computational insights into the dynamic behavior of the vaccine-TLR4 complex. Codon optimization suggested compatibility of the designed sequence with an Escherichia coli-based expression framework. Immune simulation predicted potential humoral and cellular immune response patterns, including changes in IgG, IFN-γ, and IL-2 levels. The designed mRNA sequence exhibited favorable predicted secondary structural characteristics; however, further experimental evaluation is required to assess translational efficiency and stability. Although this study is limited to computational analyses and requires experimental validation, the findings suggest that PV-GNProtecta may represent a potential candidate for further investigation against PUUV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.